Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
机构：[1]Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center,Guangzhou, China[2]Department of Hematology, Beijing Chao-Yang HospitalCapital Medical University, Beijing, China北京朝阳医院[3]Department of Hematology, HenanCancer Hospital, Henan Cancer Hospital Afliated to Zhengzhou University,Zhengzhou, China河南省肿瘤医院[4]Department of Hematology, The First Hospital of JilinUniversity, Changchun, China[5]Department of Hematology, The First AfliatedHospital of Soochow University, Jiangsu Institute of Hematology National Clinical Research Center for Hematologic Diseases, Suzhou, China[6]Departmentof Hematology, Second Hospital of Shanxi Medical University, Taiyuan, China[7]Department of Hematology and Lymphoma Research Center, Peking University Third Hospital, Beijing, China[8]Department of Hematology, ChangzhengHospital, Second Military Medical University, Shanghai, China[9]Departmentof Hematology, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China[10]Department of Hematology,Tangdu Hospital, Fourth Military Medical University, Xi’an, China[11]Instituteof Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China[12]Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, China[13]Department of Hematology, Harbin Medical University Cancer Hospital,Harbin, China[14]Department of Hematology, The Second Afliated Hospitalof Nanchang University, Nanchang, China[15]Department of Hematology,Fourth Hospital of Hebei Medical University, Shijiazhuang, China河北医科大学第四医院[16]Department of Hematology, XiJing Hospital, Fourth Military Medical University, Xi’an,China[17]Department of Hematology, West China Hospital, Sichuan University,Chengdu, China四川大学华西医院[18]Bone Marrow Transplantation Center, The First AfliatedHospital, School of Medicine, Zhejiang University, Hangzhou, China[19]Department of Hematology, Beijing Friendship Hospital, Capital Medical University,Beijing, China首都医科大学附属北京友谊医院[20]Department of Hematology, Tianjin Medical University CancerInstitute and Hospital, Tianjin, China[21]Department of Hematology, The FirstAfliated Hospital of Xiamen University and Institute of Hematology, MedicalCollege of Xiamen University, Xiamen, China[22]Department of Hematology,Qilu Hospital of Shandong University, Jinan, China[23]Department of Hematology, China-Japan Friendship Hospital, Beijing, China[24]Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Province Key Laboratory of Hematology, Fuzhou, China[25]Department of Hematology, The ThirdXiangya Hospital of Central South University, Changsha, China[26]Departmentof Hematology, Tongji Hospital of Tongji Medical College, Huazhong Universityof Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[27]Department of Hematology, TheSecond Afliated Hospital of Zhejiang University School of Medicine, Hangzhou, China[28]Department of Hematology, The First Afliated Hospital, Schoolof Medicine, Zhejiang University, Hangzhou, China[29]Department of Hematology, The Afliated Changzhou No.2 People’s Hospital of Nanjing MedicalUniversity, Changzhou, China[30]Department of Hematology, First AfliatedHospital of Nanchang University, Nanchang, China[31]Department of Hematology, Peking University First Hospital, Beijing, China[32]Department of Hematology, The Afliated Hospital of Inner Mongolia Medical University, Hohhot,China[33]Department of Hematology, General Hospital of Tianjin MedicalUniversity, Tianjin, China[34]Department of Hematology, Beijing Luhe Hospital,Capital Medical University, Beijing, China[35]Department of Hematology, UnionHospital, Tongji Medical College, Huazhong University of Science and Technology, Wunan, China[36]Beijing Sunbio Biotech Co.,Ltd.,Beijing, China
This study was funded by the National Major Science and Technology Projectsof China (grant number: 2018ZX09733003) and Beijing Sunbio Biotech. Co., Ltd.,a wholly-owned subsidiary of Wuhan Hiteck Biological Pharma Co., Ltd. Thefunder, National Major Science and Technology Projects of China, had no role inthe design, analysis, or interpretation. The funder, Beijing Sunbio, in collaborationwith the investigators, designed the trial and collected and interpreted the data.
第一作者机构：[1]Department of Hematologic Oncology, Sun Yat-Sen University Cancer Center,Guangzhou, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhongjun Xia,Yun Leng,Baijun Fang,et al.Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial[J].BMC CANCER.2023,23(1):doi:10.1186/s12885-023-11489-8.
APA：
Zhongjun Xia,Yun Leng,Baijun Fang,Yang Liang,Wei Li...&Wenming Chen.(2023).Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial.BMC CANCER,23,(1)
MLA：
Zhongjun Xia,et al."Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial".BMC CANCER 23..1(2023)
医学